Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Colorado Clinical & Translational Sciences Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
This project seeks to learn more about the effects of cannabis use on the endocannabinoid system and endogenous opioid systems in adolescents to address a fundamental gap in knowledge and identify biomarkers that may help distinguish youth who relapse from youth who remain sober.
Learning the effects of cannabis use on the endocannabinoid system and endogenous opioid systems in adolescents addresses a fundamental gap in knowledge and may identify biomarkers that help distinguish youth who relapse from youth who remain sober.
The specific aims of the project are to:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Contingency Management | Experimental | Abstinence will be rewarded following a contingency management (CM) payment scale. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Contingency Management | Behavioral | Participants will be paid for abstinence at each study visit. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cannabinoid levels in blood | Cannabinoid levels in blood: Our primary measure will be 11-nor-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) concentrations in whole blood, which have been demonstrated to be a reliable quantitative measure of cannabis use over the past few weeks35. We will measure an additional 10 cannabinoids [THC, 11-hydroxy-THC, THC-glucuronide, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV), tetrahydro-cannabivarin (THCV), and THCV-COOH]34, which will be visually inspected to identify potential secondary outcomes. | Collected at Baseline |
| Cannabinoid levels in blood | Cannabinoid levels in blood: Our primary measure will be 11-nor-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) concentrations in whole blood, which have been demonstrated to be a reliable quantitative measure of cannabis use over the past few weeks35. We will measure an additional 10 cannabinoids [THC, 11-hydroxy-THC, THC-glucuronide, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV), tetrahydro-cannabivarin (THCV), and THCV-COOH]34, which will be visually inspected to identify potential secondary outcomes. | Collected at Week 2 |
| Cannabinoid levels in blood | Cannabinoid levels in blood: Our primary measure will be 11-nor-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) concentrations in whole blood, which have been demonstrated to be a reliable quantitative measure of cannabis use over the past few weeks35. We will measure an additional 10 cannabinoids [THC, 11-hydroxy-THC, THC-glucuronide, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV), tetrahydro-cannabivarin (THCV), and THCV-COOH]34, which will be visually inspected to identify potential secondary outcomes. | Collected at Week 4 |
| Cannabinoid levels in blood | Cannabinoid levels in blood: Our primary measure will be 11-nor-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) concentrations in whole blood, which have been demonstrated to be a reliable quantitative measure of cannabis use over the past few weeks35. We will measure an additional 10 cannabinoids [THC, 11-hydroxy-THC, THC-glucuronide, cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV), tetrahydro-cannabivarin (THCV), and THCV-COOH]34, which will be visually inspected to identify potential secondary outcomes. |
| Measure | Description | Time Frame |
|---|---|---|
| Endorphin levels in blood | Endorphin levels in blood: Circulating beta Endorphin (b-EP) levels will be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. | Collected at Baseline |
| Endorphin levels in blood |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The contingency management (CM) procedure will consist of a four-week abstinence-based incentive program. At the initial visit, participants will be instructed to refrain from using cannabis for the next month and abstinence will be monitored by urine and saliva drug tests. Participants will be paid at each study visit for attendance and abstinence. CM payment rates for abstinence will revert to the initial payment level following a missed study visit or if THC levels rise or are detected by saliva drug screen, respectively.
Not provided
Not provided
Not provided
Not provided
| Collected at Week 8 |
| Endocannabinoid levels in blood | We will measure endocannabinoid (eCB) levels AEA and 2-AG, the primary eCBs, in whole blood. | Collected at Baseline |
| Endocannabinoid levels in blood | We will measure endocannabinoid (eCB) levels AEA and 2-AG, the primary eCBs, in whole blood. | Collected at Week 2 |
| Endocannabinoid levels in blood | We will measure endocannabinoid (eCB) levels AEA and 2-AG, the primary eCBs, in whole blood. | Collected at Week 4 |
| Endocannabinoid levels in blood | We will measure endocannabinoid (eCB) levels AEA and 2-AG, the primary eCBs, in whole blood. | Collected at Week 8 |
Endorphin levels in blood: Circulating beta Endorphin (b-EP) levels will be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
| Collected at Week 2 |
| Endorphin levels in blood | Endorphin levels in blood: Circulating beta Endorphin (b-EP) levels will be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. | Collected at Week 4 |
| Endorphin levels in blood | Endorphin levels in blood: Circulating beta Endorphin (b-EP) levels will be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. | Collected at Week 8 |
| Cannabis Craving | Cannabis craving: The Marijuana Craving Questionnaire (MCQ) will be used to assess cannabis craving. | Collected at Baseline |
| Cannabis Craving | Cannabis craving: The Marijuana Craving Questionnaire (MCQ) will be used to assess cannabis craving. | Collected at Week 2 |
| Cannabis Craving | Cannabis craving: The Marijuana Craving Questionnaire (MCQ) will be used to assess cannabis craving. | Collected at Week 4 |
| Cannabis Craving | Cannabis craving: The Marijuana Craving Questionnaire (MCQ) will be used to assess cannabis craving. | Collected at Week 8 |